This was the stock's fourth consecutive day of gains.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3% ...

Key Takeaways Vertex Pharmaceuticals missed first-quarter profit and revenue forecasts as costs jumped.The biotech firm also ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had ...

Vertex Pharmaceuticals has authorized an additional share repurchase program of up to $4 billion. The program does not have an expiration date and can be discontinued at any time, the Boston-based ...

Vertex stock skidded Tuesday on a series of first-quarter setbacks that included light sales, slow uptake for two drugs and a paused study.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported lower-than-expected first-quarter 2025 earnings. Vertex reported ...

Vertex Pharmaceuticals (VRTX) stock faces a downgrade at Wolfe Research based on the company's recent lower than expected Q1 ...

VRTX has recorded a positive one-day return after earnings in 58% of instances. When the return is positive, the median return stands at ...